Effect of hepatitis C infection on tacrolimus doses and blood levels in liver transplantation recipients

Alimentary Pharmacology and Therapeutics

Volumn 22, Issue 1, 2005, Pages 37-44

  Trotter, J F ^a   Osborne, J C ^a   Heller, M ^a   Christians, U ^b  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; CORTICOSTEROID; CYCLOSPORIN; CYTOCHROME P450 3A4; GLYCOPROTEIN P; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; COST CONTROL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG COST; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER CLEARANCE; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEPATITIS C; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TACROLIMUS;

EID: 21744434188     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2005.02502.x     Document Type: Article

References (36)

1. Berenguer M. Natural history of recurrent hepatitis C. Liver Transpl 2002; 8: S14-8.
2. Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002; 122: 889-96.
3. Tuncer M, Suleymanlar G, Ersoy FF, Yakupoglu G. Effects of hepatitis C virus infection on cyclosporine trough levels in renal transplant patients. Transplant Proc 2000; 32: 569-71.
4. Manzanares C, Moreno M, Castellanos F, et al. Influence of hepatitis C virus infection on FK 506 blood levels in renal transplant patients. Transplant Proc 1998; 30: 1264-5.
5. Latorre A, Morales E, Gonzalez E, et al. Clinical management of renal transplant patients with hepatitis C virus infection treated with cyclosporine or tacrolimus. Transplant Proc 2002; 34: 63-4.
6. Dietl KH. European Renal Transplantation Study Group. Oral dosing of tacrolimus and cyclosporine microemulsion - results from a large multicenter study in renal transplantation. Transplant Proc 2002; 34: 1659-60.
7. van den Berg AP, Haagsma EB, Gouw AS, Slooff MJ, Jansen PL. Recurrent HCV infection reduces the requirement for tacrolimus after liver transplantation. Transplant Proc 2001; 33: 1467.
8. Trotter JF, Stolpman N, Wachs M, et al. Living donor liver transplant recipients achieve higher levels of immunosuppressants than cadaveric recipients. Liver Transpl 2002; 8: 212-8.
9. Trotter JF, Wachs M, Bak T, et al. Liver transplantation using sirolimus and minimal corticosteroids (3-day taper). Liver Transpl 2001; 7: 343-51.
10. Lampen A, Christians U, Guengerich FP, et al. Metabolism of the immunosuppressant tacrolimus in the small intestine: cytochrome P450, drug interactions and interindividual variability. Drug Metab Dispos 1995; 23: 1315-24.
11. Christians U, Jacobsen W. Benet LZ, Lampen A. Mechanisms of clinically relevant drug interactions associated with tacrolimus. Clin Pharmacokinet 2002; 41: 813-51.
12. Lo A, Burckart GJ. P-glycoprotein and drug therapy in organ transplantation. J Clin Pharmacol 1999; 39: 995-1005.
13. Yokogawa K, Takahashi M, Tamai I, et al. P-glycoprotein-dependent disposition of tacrolimus. Studies in mdr1a knockout mice. Pharm Res 1999; 16: 1213-8.
14. Bekersky I, Dressier D, Alak A, Boswell GW, Mekki QA. Comparative tacrolimus pharmacokinetics: normal vs. mildly hepatically impaired subjects. J Clin Pharmacol 2001; 41: 628-35.
15. Ptachcinski RJ, Venkataramanan R, Burckart GJ. Clinical pharmacokinetics of cyclosporine. Clin Pharmacokinet 1986; 11: 107-32.
16. Abu-Elmagd KM, Fung JJ, Alessiani M, et al. Strategy of FK-506 therapy in liver transplant patients: effect of graft function. Trans Proc 1991; 23: 2771-4.
17. Gonschior AK, Christians U, Winkler M, Linck A, Baumann J, Sewing KF. Tacrolimus (FK506) metabolite patterns in blood from liver and kidney transplant recipients. Clin Chem 1996; 42: 1426-32.
18. Herold C, Heinz R, Niedobitek G, Schneider T, Hahn EG, Schuppan D. Quantitative testing of liver function in relation to fibrosis in patients with chronic hepatitis B and C. Liver 2001; 21: 260-5.
19. Morgan ET. Regulation of cytochrome P450 by inflammatory mediators: why and how? Drug Metab Dispos 2001; 29: 207-12.
20. Nelson DR, Lim HL, Marousis CG, et al. Activation of tumor necrosis factor-alpha system in chronic hepatitis C virus infection. Dig Dis Sci 1997; 42: 2487-94.
21. Nelson DR, Gonzalez-Peralta RP, Qian K, et al. Transforming growth factor-beta 1 in chronic hepatitis C. J Viral Hepatol 1997; 4: 29-35.
22. Reiser M, Marousis CG, Nelson DR, et al. Serum interleukin 4 and interleukin 10 levels in patients with chronic hepatitis C virus infection. J Hepatol 1997; 26: 471-8.
23. Oyanagi Y, Takahashi T, Matsui S, et al. Enhanced expression of interleukin-6 in chronic hepatitis C. Liver 1999; 19: 464-72.
24. Muntane-Relat J, Ourlin JC, Domergue J, Maurel P. Differential effects of cytokines on the inducible expression of CYP1A1. CYP1A2, and CYP3A4 in human hepatocytes in primary culture. Hepatology 1995; 22: 1143-53.
25. Carlson TJ, Billings RE. Role of nitric oxide in the cytokine-mediated regulation of cytochrome P-450. Mol Pharmacol 1996; 49: 796-801.
26. Siewert E, Bort R, Kluge R, Heinrich PC, Castell J, Jover R. Hepatic cytochrome P450 down-regulation during aseptic inflammation in the mouse is interleukin 6 dependent. Hepatology 2000; 32: 49-55.
27. Muller GF, Dohr O, El-Bahay C, Kahl R, Abel J. Effect of transforming growth factor-beta1 on cytochrome P450 expression: inhibition of CYP1 mRNA and protein expression in primary rat hepatocytes. Arch Toxicol 2000; 74: 145-52.
28. Iber H, Morgan ET. Regulation of hepatic cytochrome P450 2C11 by transforming growth factor-beta, hepatocyte growth factor, and interleukin-11. Drug Metab Dispos 1998; 26: 1042-4.
29. McRae MP, Brouwer KL, Kashuba AD. Cytokine regulation of P-glycoprotein. Drug Metab Rev 2003; 35: 19-33.
30. Sukhai M, Piquette-Miller M. Regulation of the multidrug resistance genes by stress signals. J Pharm Pharm Sci 2000; 3: 268-80.
31. Sukhai M, Yong A, Pak A, Piquette-Miller M. Decreased expression of P-glycoprotein in interleukin-1beta and interleukin-6 treated rat hepatocytes. Inflamm Res 2001; 50: 362-70.
32. Hartmann G, Kim H, Piquette-Miller M. Regulation of the hepatic multidrug resistance gene expression by endotoxin and inflammatory cytokines in mice. Int Immunopharmacol 2001; 1: 189-99.
33. Walther W, Stein U. Influence of cytokines on mdr1 expression in human colon carcinoma cell lines increased cytotoxicity of MDR relevant drugs. J Cancer Res Clin Oncol 1994; 120: 417-8.
34. Stein U, Walther W, Shoemaker RH. Reversal of MDR by transduction of cytokine genes into human colon carcinoma cell lines. J Natl Cancer Inst 1996; 88: 1383-92.
35. Stein U, Weither W, Shoemaker RH. Modulation of mrd1 expression by cytokines in human colon carcinoma cells: an approach for reversal of MDR. Br J Cancer 1996; 74: 1384-91.
36. Kugelmas M, Osgood MJ, Trotter JF, et al. Hepatitis C virus therapy, hepatocyte drug metabolism, and risk for acute cellular rejection. Liver Transpl 2003; 9: 1159-65.